Compagnie Chargeurs Invest (CRI) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
17 Sep, 2026Executive summary
Completed strategic transformation and rebranding to Belgrano, focusing on high-luxury and heritage assets under the “Architect of Rarity” signature.
Achieved a major milestone with the successful sale of Novacel, generating a €51.2m capital gain and reducing net debt by €129.1m to €146.0m as of June 30, 2026.
Announced a proposed share buyback offer (OPRA) at €14.00 per share, targeting completion by Q1 2027, to optimize shareholder returns.
Strengthened equity to €285.0m and maintained a robust order book of nearly €300m in cultural businesses.
Strategic simplification, decentralization, and AI integration drive cost optimization and growth.
Financial highlights
H1 2026 revenue: €188.7m, down 14.1% year-over-year due to project phasing at Museum Studio and Novacel divestment; gross margin: €58.3m (30.9% margin, up 170 bps y/y).
Attributable net profit: €24.0m, including the Novacel capital gain.
Group equity: €285.0m; net debt: €146.0m, reflecting significant deleveraging.
EBITDA: €13.9m (7.4% margin); recurring operating profit: €5.2m (2.8% margin).
NAV: €556m (€23.0/share) as of June 30, 2026, down from €585m (€24.2/share) at year-end 2025.
Outlook and guidance
Growth expected to accelerate in H2 2026/H1 2027, targeting €500m revenue and €50m EBITDA by 2027.
Five-year targets: €750m revenue and €100m EBITDA.
Ambition to surpass €1bn in Net Asset Value by 2031.
Free cash flow generation prioritized as investment cycle ends.
OPRA share buyback at €14/share to enhance EPS and liquidity, subject to approvals.
Latest events from Compagnie Chargeurs Invest
- Q1 2026 revenue fell, but strategic transformation accelerates with Novacel divestment and strong order books.CRI
Q1 2026 - Novacel sale and strategic refocus boost financial flexibility and target €1bn NAV by 2030.CRI
Q4 2025 - Strong Q3 growth in new businesses and luxury brands, with a robust outlook for 2026.CRI
Q3 2025 - Stable H1 2025 revenue and NAV growth, strong Museum Studio gains, Novacel disposal under review.CRI
Q2 2025 - Q3 2024 revenue up 11.2% year-over-year, led by Novacel and Museum Studio growth.CRI
Q3 2024 - Revenue up 11.1% and recurring operating profit up 33.9%, with strong cash flow and reduced net debt.CRI
Q2 2024 - Q1 2024 revenue up 10% as Chargeurs accelerates growth in high-value, sustainable markets.CRI
Investor Presentation - Strong growth, strategic transformation, and all resolutions passed amid market and regulatory risks.CRI
AGM 2025 - Museum Studio and Personal Goods drove 5.6% revenue growth in Q1 2025 amid global challenges.CRI
Q1 2025